Check-Cap Ltd. (CHEK) Stock
Check-Cap Ltd. is an Israeli medical diagnostics company currently in the clinical development phase.
Valuation
Financials & Margins
Annual Financials (USD)
Balance Sheet (USD)
Cash Flow (USD)
Valuation & Return Ratios
Peer Comparison
About Check-Cap Ltd.
Check-Cap Ltd. is an Israeli medical diagnostics company currently in the clinical development phase. It is dedicated to advancing a novel capsule-based screening method that employs ultra-low-dose X-rays. This technology is designed to thoroughly examine the internal surface of the colon, aiming to identify precancerous polyps and other structural irregularities. The company's primary offering, the C-Scan system, is composed of three integral parts: the C-Scan Cap, an ingestible X-ray scanning capsule for detecting suspected polyps; the C-Scan Track, a disposable unit that adheres to the patient's back via biocompatible adhesive patches; and the C-Scan View software. This client/server application enables the download of procedural data from the C-Scan Track, performs detailed analysis, and generates comprehensive reports. Check-Cap Ltd. was founded in 2004 and operates from its headquarters in Isfiya, Israel.
Check-Cap Ltd. is headquartered in IL.
Check-Cap Ltd. (CHEK) stock trades at $1.86 with a market capitalization of $10.88M. The stock is valued at a price-to-earnings (P/E) ratio of -0.43, price-to-book of -7.50, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.56 and $3.13, and currently trades 40.6% below its 52-week high.
On profitability, Check-Cap Ltd. generates a return on equity (ROE) of -226.19%, an operating margin of 0.00%, a net profit margin of 0.00%.
Official website: www.check-cap.com